PsiThera

PsiThera integrates physics-based modeling into a unified platform to advance drug discovery in inflammation and immunology.

PsiThera is developing a pipeline of oral small-molecule programs that target validated immunology pathways.

Drug hunters, investors and partners expect three things from a modern, physics-native platform: clarity, precision and speed.

Conformational sampling of biomolecules is critical in drug discovery, as static structures from methods like AlphaFold fail to capture dynamic biological processes.

Accurate computational prediction of protein–ligand binding affinities remains a challenge in drug design despite decades of effort.

PsiThera merges computation with drug discovery to develop medicines for patients.

PsiThera seeks a medicinal chemist with expertise in synthetic chemistry and optimizing peptide therapeutics, particularly macrocyclic peptides, for oral delivery.

PsiThera is hiring a drug discovery biologist with experience in immune and inflammatory signaling to lead small-molecule and macrocycle programs from hit identification to IND submission.

Camil Sayegh, Ph.D is Chief Scientific Officer at PsiThera. He brings 20 years of cross-sector experience in the biotech and pharmaceutical industry.

Eric D. Shaff is President and Chief Executive Officer at PsiThera. He brings more than 20 years of leadership experience in biotechnology.

Jean-Christophe Harmange, is SVP, Drug Discovery at PsiThera. He brings more than 25 years of small molecule drug discovery.

PsiThera is advancing a paradigm shift in biotechnology by pioneering a physics-driven approach to drug design.

Contact PsiThera.

PsiThera is advancing programs across multiple targets from the TNF superfamily and beyond, where no oral therapies currently exist.